---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061539"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:53:20.920754+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Intellia reports Q3 net loss $122.2M, FDA clears NTLA-2001 Phase 3 IND for ATTR-CM

## Summary
- FDA cleared IND for NTLA-2001 Phase 3 MAGNITUDE trial in ATTR cardiomyopathy; on track to initiate by year-end.
- Phase 1 data: median serum TTR reduction 91% in 62 patients; durable reduction at 12+ months.
- NTLA-2002 Phase 2 enrollment on track to complete Q4 2023; received EMA PRIME designation for HAE.
- Expanded Regeneron collaboration in neurological and muscular diseases; $30M payment expected H1 2024.
- Q3 net loss $122.2M vs $113.2M YoY; cash, equivalents and marketable securities $992.5M.

## SEC filing metadata
- accession: 0000950170-23-061539
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000095017023061539/0000950170-23-061539-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000095017023061539/ntla-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061539
- JSON: https://secwatch.observer/filing/0000950170-23-061539.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061539.txt

## Key facts
- Earnings Releases
  Intellia Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000095017023061539/0000950170-23-061539-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.